Clopidgrel high dose evaluation for the patIent with coronary artery disease in Japan (CHOICE)
Phase 4
- Conditions
- The patient scheduled to undergo percutaneous coronary intervention due to ischemic heart disease
- Registration Number
- JPRN-UMIN000003284
- Lead Sponsor
- Department of Cardiovascular Medicine, Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
Not provided
Exclusion Criteria
the patient of ST elevation myocardial infarction the patient of Contraindication of aspirin or clopidgrel the patient undergoing anticoagulation with coumadin the patient who underwent thrombolysis within 2 weeks the patient who underwent antiplatelet therapy besides aspirin the patient who taking corticosteroid the patient who taking proton pump inhibitor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Inhibition of platelet aggregation after 24 hours since the clopidgrel loading
- Secondary Outcome Measures
Name Time Method Inhibition of platelet aggregation after a week since the clopidgrel loading The clinical and adverse event at 28 days after the PCI